|
|
Article: Mesoblast Limited (ASX:MSB) Successful Bone Marrow Regeneration In Cancer Patients Using Cord Blood Expanded By Proprietary Stem Cells
- Article from:
- abnnewswire.net
- Article date:
- November 6, 2009
- Author:
CopyrightCopyright 2009 ABN Newswire. (Hide copyright information)
|
Mesoblast Limited's (ASX:MSB)(PINK:MBLTY) today announced successful results from the first 18 patients receiving a bone marrow transplant using umbilical cord blood expanded by the patented allogeneic, or "off-the-shelf", Mesenchymal Precursor Cells (MPCs).
Mesoblast's United States-based associate company Angioblast Systems Inc. is conducting the trial at the University of Texas M. D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy. The US National Institutes of Health (NIH) has funded treatment in up to 30 patients.
Executive Director Professor Silviu Itescu told institutional investors attending the UBS Healthcare Conference in Sydney today that the ...